Niclosamide reverses SARS-CoV-2 control of lipophagy
Garrett, T.; Coatsworth, H.; Mahmud, I.; Hamerly, T.; Stephenson, C. J.; Yazd, H.; Ayers, J. B.; Miller, M.; Lednicky, J. A.; Dinglasan, R. R.
Show abstract
The global effort to combat COVID-19 rapidly produced a shortlist of approved drugs with anti-viral activities for clinical repurposing. However, the jump to clinical testing was lethal in some cases as a full understanding of the mechanism of antiviral activity as opposed to pleiotropic activity/toxicity for these drugs was lacking. Through parallel lipidomic and transcriptomic analyses we observed massive reorganization of lipid profiles of infected Vero E6 cells, especially plasmalogens that correlated with increased levels of virus replication. Niclosamide (NIC), a poorly soluble anti-helminth drug identified for repurposed treatment of COVID-19, reduced the total lipid profile that would otherwise amplify during virus infection. NIC treatment reduced the abundance of plasmalogens, diacylglycerides, and ceramides, which are required for virus production. Future screens of approved drugs may identify more druggable compounds than NIC that can safely but effectively counter SARS-CoV-2 subversion of lipid metabolism thereby reducing virus replication. However, these data support the consideration of niclosamide as a potential COVID-19 therapeutic given its modulation of lipophagy leading to the reduction of virus egress and the subsequent regulation of key lipid mediators of pathological inflammation.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Fatty Acyl Availability Modulates Cardiolipin Composition and Alters Mitochondrial Function in HeLa Cells 92%
- Endocytosis of very low-density lipoprotein particles: an unexpected mechanism for lipid acquisition by breast cancer cells 92%
- Fatty Acid Synthase inhibitor TVB-3166 prevents S-acylation of the Spike protein of human coronaviruses. 91%
Similar papers in this journal
- The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication 95%
- Rewiring of the host cell metabolome and lipidome during lytic gammaherpesvirus infection is essential for infectious virus production 95%
- Murine Norovirus infection results in anti-inflammatory response downstream of amino acids depletion in macrophages 93%
Similar papers in this journal
- The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines 94%
- Metformin Suppresses SARS-CoV-2 in Cell Culture 94%
- The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models 93%
Similar papers in this journal
- Sphingosine kinases promote Ebola virus infection and can be targeted to inhibit filoviruses, coronaviruses, and arenaviruses using late endocytic trafficking to enter cells 93%
- The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators 92%
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.